MPox
The purpose of this study is to find out how often health problems occur after an Imvamune (Mpox) vaccine
Location: British Columbia and Ontario
Study Summary
Study participants were asked to complete an online survey one week (8 days) after each dose of vaccine and 30-60 days after their last dose of Mpox vaccine. These surveys capture health problems occurring within 1 week for Dose 1 and Dose 2). In addition to those occurring more than 1 week (30-60 days) after vaccination.
Research
Summaries
In June 2022 Canada started giving the MVA-BN vaccine to protect against Mpox, especially to at-risk groups like men who have sex with men (MSM) and sex workers. The Canadian National Vaccine Safety Network (CANVAS) monitored the vaccination campaigns in Toronto and Vancouver by surveying vaccinated people seven and 30 days after each dose, and comparing this group with unvaccinated people.
Overall, nearly 1,200 people vaccinated with MVA-BN completed a survey, and most reported mild to moderate pain at the injection site. Those vaccinated with MVA-BN had fewer health problems compared to the unvaccinated group. About 8.4% of those vaccinated were HIV positive and they had less injection site pain but more health problems compared to the vaccinated group who was HIV negative, but fewer health problems than the group who was unvaccinated.
For full details on this research, please click the following link:
As with any events reports, not all symptoms reported may be caused by the vaccine. They may be coincidental and/or due to other causes.